Literature DB >> 17991399

Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe.

E J Kuijper1, B Coignard, J S Brazier, C Suetens, D Drudy, C Wiuff, H Pituch, P Reichert, F Schneider, A F Widmer, K E Olsen, F Allerberger, D W Notermans, F Barbut, M Delmée, M Wilcox, A Pearson, B C Patel, D J Brown, R Frei, T Akerlund, I R Poxton, P Tüll.   

Abstract

Recent outbreaks of Clostridium difficile-associated diarrhoea (CDAD) with increased severity, high relapse rate and significant mortality have been related to the emergence of a new, hypervirulent C. difficile strain in North America, Japan and Europe. Definitions have been proposed by the European Centre of Disease Prevention and Control (ECDC) to identify severe cases of CDAD and to differentiate community-acquired cases from nosocomial CDAD (http://www.ecdc.europa.eu/documents/pdf/Cl_dif_v2.pdf). CDAD is mainly known as a healthcare-associated disease, but it is also increasingly recognised as a community-associated disease. The emerging strain is referred to as North American pulsed-field type 1 (NAP1) and PCR ribotype 027. Since 2005, individual countries have developed surveillance studies to monitor the spread of this strain. C. difficile type 027 has caused outbreaks in England and Wales, Ireland, the Netherlands, Belgium, Luxembourg, and France, and has also been detected in Austria, Scotland, Switzerland, Poland and Denmark. Preliminary data indicated that type 027 was already present in historical isolates collected in Sweden between 1997 and 2001.

Entities:  

Mesh:

Year:  2007        PMID: 17991399     DOI: 10.2807/esm.12.06.00714-en

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  36 in total

Review 1.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

Review 2.  Hospital infection control strategies for vancomycin-resistant Enterococcus, methicillin-resistant Staphylococcus aureus and Clostridium difficile.

Authors:  B Lynn Johnston; Elizabeth Bryce
Journal:  CMAJ       Date:  2009-03-17       Impact factor: 8.262

3.  Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production.

Authors:  Michelle Merrigan; Anilrudh Venugopal; Michael Mallozzi; Bryan Roxas; V K Viswanathan; Stuart Johnson; Dale N Gerding; Gayatri Vedantam
Journal:  J Bacteriol       Date:  2010-07-30       Impact factor: 3.490

Review 4.  Clostridium difficile infection: new insights into management.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Mayo Clin Proc       Date:  2012-11       Impact factor: 7.616

5.  The evolving epidemiology of Clostridium difficile infection in Canadian hospitals during a postepidemic period (2009-2015).

Authors:  Kevin C Katz; George R Golding; Kelly Baekyung Choi; Linda Pelude; Kanchana R Amaratunga; Monica Taljaard; Stephanie Alexandre; Jun Chen Collet; Ian Davis; Tim Du; Gerald A Evans; Charles Frenette; Denise Gravel; Susy Hota; Pamela Kibsey; Joanne M Langley; Bonita E Lee; Camille Lemieux; Yves Longtin; Dominik Mertz; Lorraine Maze Dit Mieusement; Jessica Minion; Dorothy L Moore; Michael R Mulvey; Susan Richardson; Michelle Science; Andrew E Simor; Paula Stagg; Kathryn N Suh; Geoffrey Taylor; Alice Wong; Nisha Thampi
Journal:  CMAJ       Date:  2018-06-25       Impact factor: 8.262

6.  The Clostridium difficile spo0A gene is a persistence and transmission factor.

Authors:  Laura J Deakin; Simon Clare; Robert P Fagan; Lisa F Dawson; Derek J Pickard; Michael R West; Brendan W Wren; Neil F Fairweather; Gordon Dougan; Trevor D Lawley
Journal:  Infect Immun       Date:  2012-05-21       Impact factor: 3.441

7.  Clostridium difficile as a cause of healthcare-associated diarrhoea among children in Auckland, New Zealand: clinical and molecular epidemiology.

Authors:  V Sathyendran; G N McAuliffe; T Swager; J T Freeman; S L Taylor; S A Roberts
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-09       Impact factor: 3.267

8.  Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.

Authors:  Annie-Claude Labbé; Louise Poirier; Duncan Maccannell; Thomas Louie; Michel Savoie; Claire Béliveau; Michel Laverdière; Jacques Pépin
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

9.  Use of highly discriminatory fingerprinting to analyze clusters of Clostridium difficile infection cases due to epidemic ribotype 027 strains.

Authors:  W N Fawley; J Freeman; C Smith; C Harmanus; R J van den Berg; E J Kuijper; M H Wilcox
Journal:  J Clin Microbiol       Date:  2008-01-23       Impact factor: 5.948

10.  Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium.

Authors:  Richard A Stabler; Miao He; Lisa Dawson; Melissa Martin; Esmeralda Valiente; Craig Corton; Trevor D Lawley; Mohammed Sebaihia; Michael A Quail; Graham Rose; Dale N Gerding; Maryse Gibert; Michel R Popoff; Julian Parkhill; Gordon Dougan; Brendan W Wren
Journal:  Genome Biol       Date:  2009-09-25       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.